Title
Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2
Document Type
Journal Article
Publication Date
1-1-2022
Journal
Frontiers in immunology
Volume
13
DOI
10.3389/fimmu.2022.824378
Keywords
COVID-19; SARS-CoV-2; convalescence plasma; exosome; extracellular vehicles (EVs); viral treatment
Abstract
The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.
APA Citation
Taşlı, Neslihan Pakize; Gönen, Zeynep Burçin; Kırbaş, Oğuz Kaan; Gökdemir, Nur Seda; Bozkurt, Batuhan Turhan; Bayrakcı, Buse; Sağraç, Derya; Taşkan, Ezgi; Demir, Sevda; Ekimci Gürcan, Nur; Bayındır Bilgiç, Melike; Bayrak, Ömer Faruk; Yetişkin, Hazel; Kaplan, Büşra; Pavel, Shaikh Terkıs; Dinç, Gökçen; Serhatlı, Müge; Çakırca, Gamze; Eken, Ahmet; Aslan, Vedat; Yay, Mehmet; Karakukcu, Musa; Unal, Ekrem; Gül, Fethi; Basaran, Kemal Erdem; Ozkul, Yusuf; Şahin, Fikrettin; Jones, Olcay Y.; Tekin, Şaban; Özdarendeli, Aykut; and Cetin, Mustafa, "Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2" (2022). GW Authored Works. Paper 546.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/546
Department
Medicine